Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis

Psoriasis is a chronic immune-mediated disease involving complex interaction of T cells and keratinocytes. The comprehensive pathogenesis of psoriasis is not fully understood but the IL-23/Th17 axis is a central pathway in driving disease development. Guselkumab is the first treatment of moderate-to-severe psoriasis that specifically targets the p19 subunit of IL-23. The benefit of guselkumab has been established by a number of clinical trials including demonstration of greater long-term efficacy in recent comparator trials. This review addresses the results of head-to-head trials (ECLIPSE, IXORA-R, and POLARIS) that compared guselkumab to secukinumab, ixekizumab, and fumaric acid esters. The previously demonstrated long-term efficacy of guselkumab has been corroborated by many recently published studies. The effective and safe profile, convenient dosing, and improved quality of life in patients make gulselkumab a viable first-line treatment option for moderate-to-severe psoriasis.

Automated summary

Psoriasis, a chronic immune-mediated disease, involves complex interactions between T cells and keratinocytes. The IL-23/Th17 pathway plays a central role in the development of the disease, with guselkumab targeting the p19 subunit of IL-23 as a first-line treatment option for moderate-to-severe psoriasis. Recent head-to-head trials have demonstrated the long-term efficacy, safety, and improved quality of life in patients treated with guselkumab, solidifying its position as a viable treatment option.